You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 14, 2025

CLINICAL TRIALS PROFILE FOR AZACITIDINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Azacitidine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004062 ↗ Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed National Cancer Institute (NCI) Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004062 ↗ Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed Lucille P. Markey Cancer Center at University of Kentucky Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004871 ↗ Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 1 2000-05-01 RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00004871 ↗ Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed Sidney Kimmel Comprehensive Cancer Center Phase 1 2000-05-01 RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Azacitidine

Condition Name

Condition Name for Azacitidine
Intervention Trials
Acute Myeloid Leukemia 146
Myelodysplastic Syndromes 100
Myelodysplastic Syndrome 83
Chronic Myelomonocytic Leukemia 43
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Azacitidine
Intervention Trials
Leukemia 321
Leukemia, Myeloid, Acute 293
Myelodysplastic Syndromes 276
Leukemia, Myeloid 270
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Azacitidine

Trials by Country

Trials by Country for Azacitidine
Location Trials
China 245
Japan 204
France 160
Canada 146
Germany 144
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Azacitidine
Location Trials
Texas 185
New York 124
California 124
Illinois 89
Florida 84
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Azacitidine

Clinical Trial Phase

Clinical Trial Phase for Azacitidine
Clinical Trial Phase Trials
Phase 4 3
Phase 3 63
Phase 2/Phase 3 8
[disabled in preview] 231
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Azacitidine
Clinical Trial Phase Trials
Recruiting 163
Completed 163
Not yet recruiting 95
[disabled in preview] 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Azacitidine

Sponsor Name

Sponsor Name for Azacitidine
Sponsor Trials
National Cancer Institute (NCI) 100
Celgene Corporation 78
M.D. Anderson Cancer Center 61
[disabled in preview] 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Azacitidine
Sponsor Trials
Other 551
Industry 469
NIH 102
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Azacitidine: Clinical Trials, Market Analysis, and Projections

Introduction to Azacitidine

Azacitidine is a hypomethylating agent used in the treatment of various hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). Here, we will delve into the latest clinical trials, market analysis, and projections for this crucial drug.

Clinical Trials Update

SELECT-AML-1 Phase 2 Clinical Trial

In a recent update, Syros Pharmaceuticals announced the discontinuation of enrollment in the SELECT-AML-1 Phase 2 clinical trial. This trial was evaluating the combination of tamibarotene with venetoclax and azacitidine versus the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with AML and RARA gene overexpression. The decision was based on a prespecified interim analysis showing similar complete response (CR)/complete response with incomplete hematologic recovery (CRi) rates in both arms, indicating a low probability of demonstrating superiority at the final analysis[1].

Azacitidine in Higher-Risk MDS

Azacitidine remains the standard of care for higher-risk MDS, with no positive randomized trials having surpassed its efficacy. Despite numerous attempts over 17 years, azacitidine continues to show a median overall survival of 14-18 months and a 40%-50% overall response rate in real-world data. Ongoing trials, such as those combining azacitidine with venetoclax, sabatolimab, or magrolimab, are eagerly awaited for their potential to improve outcomes[4].

Subcutaneous and Oral Formulations

Studies have evaluated the pharmacokinetics and clinical effectiveness of subcutaneous and oral azacitidine formulations. Evidence suggests that subcutaneous azacitidine can prolong disease-free survival in AML patients who have achieved complete remission and are ineligible for stem cell transplant. The pharmacokinetic profiles of oral and subcutaneous formulations differ, with subcutaneous administration showing promising results in maintaining detectable plasma levels[3].

Market Analysis

Current Market Size and Growth

The global azacitidine market was valued at USD 77.51 million in 2022 and is projected to reach USD 142.41 million by 2030, growing at a CAGR of 7.9% during the forecast period of 2023-2030. Another report indicates a slightly lower growth rate, with the market expected to reach USD 112.4 million by 2030, growing at a CAGR of 3.4% from 2023 to 2030[2][5].

Market Drivers

Several factors are driving the growth of the azacitidine market:

  • Regulatory Approvals: Recent FDA approvals for drugs like Inqovi tablets for the treatment of MDS and CMML have expanded treatment options and boosted market growth[2].
  • Increasing Cancer Prevalence: The rise in chronic diseases such as breast cancer and melanoma, as well as the growing incidence of AML and MDS, are key drivers[2].
  • Awareness and Education: Efforts by government organizations and pharmaceutical companies to raise awareness about MDS have contributed to market growth[2].

Market Restraints

Despite the positive trends, there are challenges:

  • Late Approvals: Delays in regulatory approvals can hinder market growth.
  • Competition: The presence of generic versions and other hypomethylating agents can impact the market share of branded azacitidine products[2].

Market Segmentation

By Type

The azacitidine market is segmented into different types, including 99.5% purity and less than 99.5% purity. The market also includes branded products like Vidaza and generic versions[2].

By Application

Azacitidine is used in various hematological malignancies, including refractory anemia, refractory anemia with excess blasts, chronic myelomonocytic leukemia, and others[2].

By Route of Administration

The drug is administered through injectable, oral, and other routes. Subcutaneous administration has shown promising results in recent studies[2][3].

By Distribution Channel

The market is segmented by distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Hospitals and specialty clinics are significant end-users[2].

Regional Analysis

North America

North America dominates the azacitidine market due to high healthcare expenditures and a well-established healthcare infrastructure. The region is expected to continue its leadership in the market[2].

Asia-Pacific

The Asia-Pacific region is anticipated to be the most lucrative market due to increasing demand for active pharmaceutical ingredients and growing healthcare needs[2].

Key Players

The azacitidine market is characterized by the presence of several key players, including:

  • Celgene
  • Mylan
  • Shilpa Medicare
  • Accord Healthcare
  • Natco Pharma
  • Dr. Reddy's Laboratories
  • MBA Pharmaceuticals Pvt Ltd
  • Taj Generics
  • Getwell Oncology
  • EVER Pharma
  • Xpreza
  • Shubham Pharmaceutical
  • Rizochem Pharmaceutical[5].

Future Projections

Market Growth

The azacitidine market is expected to grow significantly over the next few years, driven by increasing regulatory approvals, rising awareness about MDS, and the expanding use of azacitidine in various hematological malignancies.

Emerging Trends

Combination therapies, such as azacitidine with venetoclax or other agents, are likely to become more prominent as they show promising results in clinical trials. The development of new formulations, such as oral and subcutaneous azacitidine, will also play a crucial role in market expansion[4].

Key Takeaways

  • Clinical Trials: Azacitidine remains a cornerstone in the treatment of MDS and AML, with ongoing trials exploring combination therapies.
  • Market Growth: The global azacitidine market is projected to grow at a CAGR of 7.9% or 3.4% depending on the source, reaching USD 142.41 million or USD 112.4 million by 2030.
  • Market Drivers: Regulatory approvals, increasing cancer prevalence, and awareness campaigns are driving market growth.
  • Regional Analysis: North America and Asia-Pacific are key regions, with North America leading due to its robust healthcare infrastructure.

FAQs

What is the current market size of the azacitidine market?

The global azacitidine market was valued at USD 77.51 million in 2022 or USD 91 million in 2023, depending on the source[2][5].

What is the projected growth rate of the azacitidine market?

The market is expected to grow at a CAGR of 7.9% or 3.4% from 2023 to 2030, reaching USD 142.41 million or USD 112.4 million by 2030[2][5].

What are the main applications of azacitidine?

Azacitidine is primarily used in the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML)[2][4].

Who are the key players in the azacitidine market?

Key players include Celgene, Mylan, Shilpa Medicare, Accord Healthcare, Natco Pharma, and several others[5].

What are the emerging trends in the azacitidine market?

Emerging trends include the development of combination therapies and new formulations such as oral and subcutaneous azacitidine[4].

Sources

  1. Syros Pharmaceuticals. Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial. August 12, 2024.
  2. Data Bridge Market Research. Global Azacitidine Market – Industry Trends and Forecast to 2030.
  3. CADTH Health Technology Review. Subcutaneous Injection of Azacitidine for the Treatment of Acute Myeloid Leukemia.
  4. ASH Publications. Frontline treatment options for higher-risk MDS: can we move past azacitidine? December 8, 2023.
  5. Valuates Reports. Global Azacitidine Drug Market Research Report 2024.
Last updated: 2025-01-03

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.